You're contacting media contact of this press release
Title: CoreAgeRx Launches Advanced Preventive Longevity Protocols Featuring Microdosing Semaglutide, Microdosing Tirzepatide, and Sermorelin Therapies
Sheridan, WY, United States, 21st Aug 2026 - As the landscape of health and wellness shifts from reactive treatments to proactive healthspan optimization, CoreAgeRx is proud to announce the launch of its new Preventive Longevity protocols. Designed to support long-term metabolic health, optimal body composition, and cellular rejuvenation, this innovative suite of treatments features Micro Dosing Semaglutide, Micro Dosing Tirzepatide, and Sermorelin therapy.By leveraging low, consistent dosing and natural bioidentical peptides, these protocols diverge from traditional high-dose weight loss treatments to focus on sustainable metabolic resilience and healthy aging. CoreAgeRx provides unparalleled accessibility to these advanced therapies through a 100% online, confidential platform. Patients receive care from US board-certified doctors, medications compounded exclusively in the USA by trusted pharmacies, and fast, free delivery directly to their doors; all without the burden of long-term contracts.Semaglutide Microdosing Therapy: The Low Dose Longevity Protocol Starting at just $149 per month, the Semaglutide Microdosing Therapy represents a breakthrough longevity-focused approach to metabolic health. Unlike conventional high-dose regimens aimed solely at rapid weight loss, this low-dose protocol utilizes consistent dosing to optimize insulin sensitivity, enhance glucose control, and support long-term physiological function.Patients utilizing the Semaglutide Low Dose Longevity Protocol can expect benefits that align closely with advanced healthspan goals. By promoting stable energy levels and reducing glycemic variability, the therapy supports lean body composition and metabolic stability. Furthermore, microdosing offers a significantly lower side effect profile, maki...
This press release is issued by King Newswire